Daniel Flynn - Deciphera Pharmaceuticals Founder, Chief Scientific Officer
| DCPHDelisted Stock | USD 13.32 0.36 2.63% |
Founder
Mr. Daniel L. Flynn is Founder, Executive Vice President, Chief Scientific Officer of the Company. He previously served as Decipheras President and Chief Executive Officer from November 2003 to March 2014 and as a member of our Board of Directors from November 2003 to September 2015. Before founding Deciphera in 2003, Dr. Flynn held senior roles in small molecule chemistry with various biotechnology and pharmaceuticals companies, including as Senior Director of Chemistry with Millennium Pharmaceuticals, Director, Medicinal Chemistry at Amgen Inc., and Director of Medicinal Chemistry, Combinatorial Chemistry and Research Fellow at Monsanto Company, G.D. Searle Unit. Dr. Flynn is currently Adjunct Professor of Medicinal Chemistry at the University of KansasLawrence and has served as the national Chair for the Division of Medicinal Chemistry of the American Chemical Society since 2019.
| Age | 69 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 781 209 6400 |
| Web | https://www.deciphera.com |
Daniel Flynn Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Flynn against Deciphera Pharmaceuticals stock is an integral part of due diligence when investing in Deciphera Pharmaceuticals. Daniel Flynn insider activity provides valuable insight into whether Deciphera Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Deciphera Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Deciphera Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Flynn over six months ago Disposition of 2403 shares by Daniel Flynn of Deciphera Pharmaceuticals at 21.2413 subject to Rule 16b-3 |
Deciphera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2662) % which means that it has lost $0.2662 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5037) %, meaning that it created substantial loss on money invested by shareholders. Deciphera Pharmaceuticals' management efficiency ratios could be used to measure how well Deciphera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Deciphera Pharmaceuticals LLC currently holds 25.88 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Deciphera Pharmaceuticals has a current ratio of 5.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Deciphera Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | FOUNDER Age | ||
| BA MD | Neurocrine Biosciences | 76 | |
Management Performance
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 |
Deciphera Pharmaceuticals Leadership Team
Elected by the shareholders, the Deciphera Pharmaceuticals' board of directors comprises two types of representatives: Deciphera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Deciphera. The board's role is to monitor Deciphera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Deciphera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Deciphera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Flynn, Founder, Chief Scientific Officer | ||
| Daniel Martin, Chief Commercial Officer | ||
| Margarida Duarte, Senior International | ||
| Stephen Ruddy, VP Officer | ||
| Kevin Brodbeck, Senior Officer | ||
| Lisa Price, Senior Officer | ||
| Matthew MD, Executive Officer | ||
| Jeffrey JD, Senior Counsel | ||
| Steven Hoerter, President CEO | ||
| Dashyant Dhanak, Executive Officer | ||
| Thomas JD, CFO VP | ||
| Jennifer Larson, Senior Relations | ||
| Jama Pitman, Quality Regulatory |
Deciphera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Deciphera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.09) % | |||
| Operating Margin | (1.09) % | |||
| Current Valuation | 1.97 B | |||
| Shares Outstanding | 86.48 M | |||
| Shares Owned By Insiders | 28.48 % | |||
| Shares Owned By Institutions | 72.03 % | |||
| Number Of Shares Shorted | 3.92 M | |||
| Price To Earning | (6.78) X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |